Navigation Links
Helix BioPharma Announces Q2 2009 Financial Results
Date:3/16/2009

AURORA, Ontario, March 16 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second quarter of fiscal 2009, ended January 31, 2009.

RECENT HIGHLIGHTS

  • Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission which became effective on March 12, 2009

  • Helix received regulatory approval to commence a small European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials

  • Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

Results from Operations

Three and six month periods ended January 31, 2009 compared to the same periods in the previous year

Loss for the period

The Company recorded a loss of $4,252,000 and $6,573,000, respectively, for the three and six month periods ended January 31, 2009, for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a loss of $1,526,000 and $3,170,000, respectively, for a loss per common share of $0.04 and $0.08, respectively.

Revenues

Total revenues for the three month period ended January 31, 2009 totaled $863,000 (2008 - $791,000), resulting in an increase of $72,000 or 9.1%. Total revenues, for the six month period ended January 31, 2009 totaled $1,982,000 (2008 - $1,676,000), resulting in an increase of $306,000 or 18.3%.

Product Revenue

Product revenue totaled $740,000 and $1,661,000 respectively for the three and six month periods ended January 31, 2009 and represent an increase of $88,000 (13.5%
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... 15, 2014 METTLER TOLEDO is ... tool, ParticleView V19 with PVM technology , ... particle vision and measurement tool continuously captures high-resolution ... ParticleView V19 then automatically prepares a report pairing ... size and concentration changes. This compelling blend of ...
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Nov. 10, 2011 ChemoCentryx, Inc. today announced positive ... 44th Annual Meeting of the American Society of Nephrology. ... robust improvements of albuminuria, serum markers of renal function, ... poster presentation titled "CCR2 Inhibition in Diabetic Mice Results ...
... CRANBURY, N.J., Nov. 10, 2011 Palatin Technologies, Inc. (NYSE ... fiscal year 2012 financial results on Tuesday, November 15, 2011 ... Palatin will also conduct a conference call and live audio ... 2011, which will include discussion of the results of operations ...
... a material that absorbs on average more than 99 ... that hits it -- a development that promises to ... of engineers at NASA,s Goddard Space Flight Center in ... Optics and Photonics conference, the largest interdisciplinary technical meeting ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011 2NASA develops super-black material that absorbs light across multiple wavelength bands 2NASA develops super-black material that absorbs light across multiple wavelength bands 3
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)... CHICAGO , Nov. 11, 2014  Forensicon, Inc., ... eDiscovery firm, is pleased to announce the promotion of ... to Director of Digital Forensics. In Schiff,s new role ... out the team of digital forensics examiners and provide ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... November 18, 2009Quantitative polymerase chain reaction (qPCR) technology ... expansion as a result of advances such as ... optimization-free multiplexing, reports Genetic Engineering & Biotechnology News ... simultaneously quantify specific DNA sequences is increasing its ...
... moa, a giant extinct bird, has revealed a new geological ... in the Proceedings of the National Academy of Sciences ... University of Adelaide has reconstructed a history of marine barriers, ... of years, using the first complete genetic history of the ...
... , , KIEV, Ukraine, Nov. 17 ... including designer fashions, precious gems, antiques and fine art, has ... around the world. The International Chamber of Commerce estimates ... However, an exciting new technology can give brands and ...
Cached Biology News:Extinct moa rewrites New Zealand's history 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 3
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Visualizer Extraction Kit is manufactured for DNA ... damage byexposure to UV light. The Purification ... often used for DNA-cloning work. The conventional ... and exposure of UV light damages DNA ...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Biology Products: